Maxim Group Downgrades Matinas BioPharma Hldgs to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has downgraded Matinas BioPharma Holdings from a Buy to a Hold rating, as per analyst Jason McCarthy.
October 31, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Maxim Group analyst Jason McCarthy has downgraded Matinas BioPharma Holdings from a Buy to a Hold rating, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's potential performance, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100